ES8704079A1 - Procedimiento para producir un preparado de teofilina con accion retardada - Google Patents

Procedimiento para producir un preparado de teofilina con accion retardada

Info

Publication number
ES8704079A1
ES8704079A1 ES550291A ES550291A ES8704079A1 ES 8704079 A1 ES8704079 A1 ES 8704079A1 ES 550291 A ES550291 A ES 550291A ES 550291 A ES550291 A ES 550291A ES 8704079 A1 ES8704079 A1 ES 8704079A1
Authority
ES
Spain
Prior art keywords
sustained
theophylline
release theophylline
water
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES550291A
Other languages
English (en)
Other versions
ES550291A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Byk Gulden Lomberg Chemische Fabrik GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byk Gulden Lomberg Chemische Fabrik GmbH filed Critical Byk Gulden Lomberg Chemische Fabrik GmbH
Publication of ES550291A0 publication Critical patent/ES550291A0/es
Publication of ES8704079A1 publication Critical patent/ES8704079A1/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

PROCEDIMIENTO PARA PRODUCIR UNA PREPARACION DE TEFILINA DE ACCION RETARDADA. COMPRENDE: A) ROCIAR SOBRE 89 PARTES EN PESO DE GRANULOS DE AZUCAR UNA SOLUCION (A), PARA OBTENER GRANULOS DE MATRIZ DE TEOFILINA; B) REVESTIR A 3.900 PARTES EN PESO DE GRANULOS DE MATRIZ DE A) CON 92 PARTES EN PESO DE LACTOSA MICRONIZADA SUSPENDIDA EN UNA SOLUCION (B); C) CUBRIR A OTRAS 3.900 PARTES EN PESO DE GRANULOS DE MATRIZ DE A) CON 56 PARTES EN PESO DE LACTOSA MICRONIZADA SUSPENDIDA EN UNA SOLUCION (C); D) SECAR A LOS GRANULOS DE MATRIZ REVESTIDOS SEGUN B) Y C) CON AIRE CALIENTE ENTRE 50 Y 70JC Y DURANTE 20 A 40 MINUTOS; Y E) CARGAR JUNTOS EN UNA CAPSULA A LOS GRANULOS DE MATRIZ QUE TIENEN 200 MG DE TEOFILINA EXENTA DE AGUA. LA SOLUCION (A) ESTA FORMADA POR 800 PARTES EN PESO DE TEOFILINA SUSPENDIDAS EN UNA SOLUCION DE 40 PARTES EN PESO DE ETILCELULOSA Y DE POLIVINILPIRROLIDONA EN 800 PARTES EN VOLUMEN DE ALCOHOL ETILICO Y 1.200 PARTES DE VOLUMEN SE SOPROPANOL; LA SOLUCION (B) ESTA FORMADA POR 92 PARTES ENPESO DE ACETATO-BUTIRATO DE CELULOSA Y 9,2 PARTES EN PESO DE CITRATO ACETIL-TRIETILICO EN 920 PARTES EN VOLUMEN DE ACETONA Y DE ISOPROPANOL Y LA SOLUCION (C) ESTA COMPUESTA POR 56 PARTES EN PESO DE ACETATO-BUTIRATO DE CELULOSA Y 5,6 PARTES EN PESO DE CITRATO ACETIL-ATRIETILICO EN 5.600 PARTES EN VOLUMEN DE ACETONA E ISOPROPANOL.
ES550291A 1984-12-21 1985-12-20 Procedimiento para producir un preparado de teofilina con accion retardada Expired ES8704079A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH611184 1984-12-21
CH268385 1985-06-24

Publications (2)

Publication Number Publication Date
ES550291A0 ES550291A0 (es) 1987-04-01
ES8704079A1 true ES8704079A1 (es) 1987-04-01

Family

ID=25691137

Family Applications (1)

Application Number Title Priority Date Filing Date
ES550291A Expired ES8704079A1 (es) 1984-12-21 1985-12-20 Procedimiento para producir un preparado de teofilina con accion retardada

Country Status (20)

Country Link
US (1) US4803080A (es)
EP (1) EP0185331B1 (es)
KR (1) KR920006910B1 (es)
CN (1) CN1008060B (es)
AU (1) AU581274B2 (es)
BG (1) BG60833B2 (es)
CA (1) CA1261268A (es)
CS (1) CS396391A3 (es)
DE (1) DE3572924D1 (es)
DK (1) DK164843C (es)
ES (1) ES8704079A1 (es)
FI (1) FI84782C (es)
GR (1) GR853051B (es)
HU (1) HU193359B (es)
IE (1) IE58246B1 (es)
IL (1) IL77322A (es)
NO (1) NO171827C (es)
NZ (1) NZ214534A (es)
PT (1) PT81714B (es)
SK (1) SK278868B6 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753945A (en) * 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
GB8628728D0 (en) * 1986-12-02 1987-01-07 Euro Celtique Sa Spheroids
EP0327295A3 (en) * 1988-02-01 1989-09-06 F.H. FAULDING & CO. LTD. Tetracycline dosage form
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5196203A (en) * 1989-01-06 1993-03-23 F. H. Faulding & Co. Limited Theophylline dosage form
DE3929864A1 (de) * 1989-09-08 1991-03-14 Nordmark Arzneimittel Gmbh Verfahren zur herstellung von theophyllin-pellets
GB2284761A (en) * 1993-12-03 1995-06-21 Euro Celtique Sa Prophylactic treatment of asthma
WO2006080029A1 (en) * 2005-01-27 2006-08-03 Alembic Limited Extended release formulation of levetiracetam
US20080014271A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
US8623924B2 (en) 2011-07-15 2014-01-07 Nusirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
AU2013344753B2 (en) 2012-11-13 2018-09-27 Nusirt Sciences, Inc. Compositions and methods for increasing energy metabolism
US20150359771A1 (en) 2013-01-15 2015-12-17 Nusirt Sciences, Inc. Treating pulmonary conditions
CA2902879C (en) 2013-03-15 2023-09-26 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
SG11201607075TA (en) 2014-02-27 2016-09-29 Nusirt Sciences Inc Compositions and methods for the reduction or prevention of hepatic steatosis
JP6826730B2 (ja) * 2015-04-16 2021-02-10 学校法人 関西大学 抗氷核活性剤
CN106176682A (zh) * 2016-08-30 2016-12-07 铜陵翔宇商贸有限公司 茶碱缓释制胶囊剂及其制备方法
WO2020067887A1 (en) 2018-09-24 2020-04-02 Erasmus University Medical Center Rotterdam Specific inhibition of janus kinase 3 (jak3) for modulating anti-tumor immune responses
GB202001237D0 (en) * 2020-01-29 2020-03-11 Sisteks D O O Granular pharmaceutical product for oral administration from a pre-filled straw and method of manufacturing such pharmaceutical product

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1091289B (de) * 1956-01-25 1960-10-20 Hans Lowey Verfahren zur Herstellung einer oral anzuwendenden Arzneiform mit verlaengerter Wirkungsdauer
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
DE3278491D1 (en) * 1981-07-15 1988-06-23 Key Pharma Sustained release theophyline
US4587118A (en) * 1981-07-15 1986-05-06 Key Pharmaceuticals, Inc. Dry sustained release theophylline oral formulation
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
DE3435325A1 (de) * 1983-04-09 1986-04-17 Nikken Chemicals Co., Ltd., Tokio/Tokyo Langzeitwirkende theophyllin-tablette und verfahren zu deren herstellung

Also Published As

Publication number Publication date
NO171827B (no) 1993-02-01
PT81714A (de) 1986-01-01
DE3572924D1 (en) 1989-10-19
EP0185331A1 (de) 1986-06-25
US4803080A (en) 1989-02-07
CA1261268A (en) 1989-09-26
DK164843C (da) 1993-01-11
FI84782B (fi) 1991-10-15
CN1008060B (zh) 1990-05-23
CS396391A3 (en) 1992-06-17
AU581274B2 (en) 1989-02-16
IE853107L (en) 1986-06-21
KR920006910B1 (ko) 1992-08-22
ES550291A0 (es) 1987-04-01
DK164843B (da) 1992-08-31
PT81714B (pt) 1988-04-21
CN85109688A (zh) 1986-06-10
SK278868B6 (sk) 1998-04-08
GR853051B (es) 1986-02-03
DK600485D0 (da) 1985-12-20
NO855215L (no) 1986-06-23
AU5161885A (en) 1986-07-17
FI854973A0 (fi) 1985-12-16
KR860004634A (ko) 1986-07-11
EP0185331B1 (de) 1989-09-13
IE58246B1 (en) 1993-08-11
IL77322A (en) 1990-07-12
NO171827C (no) 1993-05-12
DK600485A (da) 1986-06-22
NZ214534A (en) 1988-08-30
HUT40334A (en) 1986-12-28
FI854973A (fi) 1986-06-22
HU193359B (en) 1987-09-28
BG60833B2 (bg) 1996-04-30
FI84782C (fi) 1992-01-27

Similar Documents

Publication Publication Date Title
ES8704079A1 (es) Procedimiento para producir un preparado de teofilina con accion retardada
GR3035627T3 (en) A mammalian cytokine, il-11.
AU579355B2 (en) Storage-stable, quick disintegrating pressed shapes containing pharmaceutical active substances
ES8706767A1 (es) Un procedimiento para fabricar una estructura absorbente a base de hidrogel y fibras de pasta de madera.
AU693747B2 (en) Imidazo(4,5-c)pyridin-4-amines
AU1061988A (en) Phosphinothricin-resistance gene active in plants, and its use
NZ223372A (en) Drug-containing jellifiable pellets
GR3033146T3 (en) Modified polypeptides with increased biological activity
AU580747B2 (en) Fibrinolytic enzyme blocked by human protein
ES8403157A1 (es) Un metodo de preparar sustancias biologicamente activas que tienen actividad anti-tumoral.
IL75936A0 (en) Controlled-release microcapsules of regulatory peptides,processes for their preparation and injection formulations
ZA937102B (en) Polypeptides involved in the biosynthesis of streptogramins, nucleotide sequences coding for these polypeptides and their use
ES8707488A1 (es) Un metodo para preparar maleato de 2-terc-butilamino-3'-cloropropiofenona
AR244756A1 (es) Nuevos monomeros y polimeros coloreados, procedimiento de preparacion de dichos polimeros y procedimiento de separacion de sustancias biologicamente activas mediante el uso de dichos polimeros.
IL75428A (en) 29-substituted milbemycins,their preparation and the use thereof in pest control
IL88381A (en) Peptide structures, immunogens containing them and their uses in the control of fertility
AU3359589A (en) Matrix membrane
ZA946008B (en) Novel tripeptides useful in immune and cns therapy
CA2071625A1 (en) A pharmaceutical preparation containing a thrombolytically active substance
AU1514288A (en) Rocking chair
ES8406504A1 (es) Procedimiento de preparacion de dinucleosidos-monofosfatos
EG18799A (en) Phenylthioureas, phenylisothioureas and phenylcarbodumides their preparation and use in the control of pests
AU6157190A (en) Substituted n-heterocycles, their preparation and their use
HU903015D0 (en) Herbicide preparations containing diazepin as active agent and process for the production of the herbicide active agent
AU106796S (en) A set of four office chairs comprising two high-backed and two low-backed chairs.

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20070205